Corporate & QHSE Policy
Laboratoire PAREVA is a family-owned business that was founded in 1994, initially as an activity integrated into its parent company, and gradually became autonomous, with its legal creation in 2006 and its full legal independence on January 1, 2012. Since then, SASU Laboratoire PAREVA has been the sole subsidiary of SAS Pareva Holding.
Specialized in the manufacturing and distribution of an active biocidal substance: PolyHexaMethylene Biguanide Hydrochloride (PHMB), our company offers this molecule as is in a 20% solution.
PHMB is used in many sectors, confirming our position as one of the reference players in the biocides value chain.
We are based in Saint-Martin-de-Crau in the Bouches-du-Rhône department, and as a manufacturer of a substance dangerous to the environment, our production site is classified as SEVESO low threshold, subject to an Operating Authorization issued by Prefectural Decree (25 January 2023).
At Laboratoire PAREVA, we place sustainability and environmental performance at the heart of our strategy. Our approach is structured around:
- Continuous improvement of our processes to reduce our ecological footprint,
- Concrete actions aimed at sustainably transforming our company,
- Active contribution to environmental preservation, in alignment with societal and regulatory challenges.
Our belief: responsible innovation and operational excellence are the pillars of sustainable growth, serving our customers and the environment.
In this context, we have already implemented several initiatives demonstrating our commitment to the environment. Among these, we can mention:
- the reduction of our energy consumption through process optimization,
- the recycling of one of our fatal by-products,
- the replacement of our gas boiler in 2022, which allowed significant gas savings and reduced our environmental footprint,
- as well as raising employee awareness of environmental issues (industrial waste sorting, environmental cleanliness, resource management, etc.).
In 2024, we insulated part of the process network. This initiative aims:
- to prevent heat loss during the production process,
- to improve operator safety,
- to minimize energy loss and thus reduce our overall consumption and CO₂ emissions by thermally insulating these pipes.
In 2025, we analysed the IED/BREF file (which compiles the best production practices in the chemical industry) and identified several actions to limit our emissions into water and the atmosphere. The main action for 2026, defined by this diagnosis, is an operational objective to reduce emissions of certain pollutants into the air. The specifications for the considered technology (stripper) will be defined during the first half of 2026, and investments will be launched in Q3 2026.
As a company committed to continuous improvement, we will continue to explore new opportunities to reduce our environmental impact and contribute to a more sustainable future for all.
The marketing of our substance is subject to numerous regulations and/or specific registrations for each geographical area; among others, we note its adoption under the Biocidal Products Regulation (BPR) in Europe and its approval by the EPA (Environmental Protection Agency) for the American market. Laboratoire PAREVA has committed to a strategic process of renewing these adoptions in Europe and the USA, as well as registrations for other geographical areas.
Our ambition is to diversify our commercial offering through different qualities of PHMB developed to meet various regulatory, professional, or geographical specifications.
Our primary goal is to better meet the satisfaction and specifications of our customers through our Quality Management System (QMS), required by our ISO 9001 certification, which has been in place since 2020. Laboratoire PAREVA has set itself a new objective: ISO 13485 certification. We are currently implementing an action plan to obtain ISO 13485 certification by November 2026. This certification will allow us to produce medical device quality PHMB and become a critical ISO 13485 certified supplier of PHMB.
In the longer term, Laboratoire PAREVA aims to comply with Good Manufacturing Practices (GMP) Part II and obtain manufacturing authorization under GMP for our PHMB by 2027.
These approaches strengthen our commitment to operational excellence and partner satisfaction.
To ensure the deployment of this policy, all staff will develop appropriate behaviour on a daily basis and will commit, in particular, to:
- Carry out daily tasks with professionalism and vigilance,
- Adopt responsible behaviour, particularly by avoiding risky situations,
- Report all malfunctions in real time,
- Develop upward and downward communication to share the company’s strategic data,
- Recognize and respect the value of each individual,
- Not use or disclose company data for external purposes.
Our strategy is to sustain our expertise, remain competitive, be recognized for our seriousness, and become the leader in the manufacturing and marketing of PHMB.
Our move upmarket and diversification through new certifications is based on our ability to offer different grades of PHMB for the biocides market, cosmetics (as a preservative), and our future ability to offer new grades as a supplier of critical material for the pharmaceutical industry and medical instrument segment. All while maintaining a balance to meet the need for quality of life at work and respect for the environment.
Management has also identified the following major challenges:
- Maintaining team engagement through a good balance between professional and private life,
- Developing the organizational agility of the company to promote innovation, particularly through training,
- Promoting a culture of prevention of health and safety risks at work,
- Contributing to building an attractive and pleasant company to attract and retain talent within our team,
- Creating wealth and employment while respecting the environment.
